were named "Company of the Year" by The Boston Globe. The company then introduced preconditioning services in 2005 to provide their customers with study-ready animals. In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland. In April 2019, Charles River announced it will be ceasing its San Diego operations, moving the work to one of its sites in Northern California. In California, the company also has sites in the town of Hollister and in South San Francisco. The work done in San Diego—the breeding of rodents that scientists use to test compounds—was moved to Hollister, California. The chairman and chief executive officer is James C. Foster, the son of founder Henry Foster. In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD. Acquisitions In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch. In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. Proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal. From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China. The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish themselves as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development. In July 2015, the company announced it would acquire Celsis International for $212 million. In January 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash. In June, the company announced it would acquire Blue Stream Laboratories. In August 2017, the business announced it would acquire Brains On-Line. In January 2018, the company announced it would acquire KWS BioTest